ERT Acquires eClinical Insights
ERT announced the acquisition of eClinical Insights
ERT, a global solution provider for high-quality patient safety and efficacy endpoint data collection, announced the acquisition of eClinical Insights, a provider of cloud-based clinical trials management software.
eClinical Insights' technology platform includes a suite of products--InTrial Metrix, TrialOps Director, Dataflow Manager, EndPoint Reviewer--that work across disparate systems and diverse global clinical trials teams. On average, clinical trial sponsors utilize between 5-7 systems for data collection from disparate vendors. ERT’s EXPERT platform combined with eClinical Insights' product suite,will enable clients to benefit from a data integration layer that enables real-time data exchange between systems. The end result is comprehensive insight into investigative site and outcomes data activity across all spectrums.
eClinical Insights had changed its name from PharmaPros almost one year ago.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
